OPEN ACCESS Freely available online

Journal of Hematology & Thromboembolic Diseases

Opinion Article

Role of Erythrocytes in the Pathological Development of Diabetic Complications

Adrian Solberg*

Department of Biomedical Sciences, Northshore University, Oslo, Norway

DESCRIPTION

Erythrocytes, or Red Blood Cells (RBCs), play a central yet often underrecognized role in the progression of diabetic complications. While diabetes mellitus is primarily characterized by chronic hyperglycemia and metabolic dysregulation, its long-term complications arise from complex interactions among vascular, inflammatory and hematological processes. Among these, erythrocyte dysfunction has emerged as a critical contributing factor.

In individuals with diabetes, persistent hyperglycemia leads to non-enzymatic glycation of hemoglobin and erythrocyte membrane proteins, resulting in the formation of Advanced Glycation End Products (AGEs). These biochemical alterations compromise erythrocyte deformability and impair their ability to traverse microcapillaries, thereby contributing to microvascular ischemia. Moreover, glycated erythrocytes exhibit reduced antioxidant capacity, making them vulnerable to oxidative stress-one of the major drivers of endothelial injury in diabetic microangiopathy.

Another significant pathological consequence is the alteration in erythrocyte membrane fluidity, which affects the cell's lifespan and promotes hemolysis. Shortened RBC survival increases the turnover of damaged cells, exacerbating inflammation and placing additional stress on erythropoiesis. The release of free hemoglobin and iron during hemolysis further accelerates oxidative stress, creating a vicious cycle that promotes vascular dysfunction. Additionally, diabetes-induced changes in erythrocyte Nitric Oxide (NO) metabolism impair their regulatory role in vascular tone. Reduced NO availability contributes to endothelial stiffness, impaired vasodilation and heightened platelet aggregation-all of which raise the risk of cardiovascular events, a leading cause of morbidity in diabetes.

In diabetic retinopathy and nephropathy, erythrocyte abnormalities are particularly damaging. The reduced deformability of RBCs hinders oxygen delivery to retinal and renal tissues, worsening hypoxia and stimulating pathological angiogenesis. Furthermore, increased erythrocyte adhesion to the endothelium-mediated by upregulated adhesion molecules such as Intercellular Adhesion Molecule-1(ICAM-1) and Vascular Cell Adhesion Molecule-1(VCAM-1)-contributes to capillary blockage, inflammation and tissue damage.

In diabetic neuropathy, impaired microcirculatory flow due to rigid erythrocytes reduces nutrient supply to peripheral nerves, accelerating neural degeneration. Recent studies also highlight the role of erythrocytes as mediators of low-grade chronic inflammation, a hallmark of diabetes. Modified RBCs can interact with immune cells, amplifying inflammatory cytokine production, thereby influencing the progression of both microvascular and macrovascular complications.

Collectively, erythrocyte dysfunction plays a multifaceted role in the pathological development of diabetic complications by contributing to oxidative stress, microvascular impairment, inflammation and endothelial dysfunction. Understanding these mechanisms highlights the importance of early metabolic control and opens avenues for novel therapeutic strategies aimed at improving erythrocyte health. Potential interventions-such as antioxidants, agents enhancing RBC deformability and therapies targeting glycation pathways.

CONCULSION

As research continues to unravel the hematological dimensions of diabetic pathology, erythrocytes are increasingly recognized not merely as passive carriers of oxygen but as active participants in disease progression. Addressing their dysfunction may help reduce the long-term complications that continue to impose significant clinical and socioeconomic burdens on individuals living with diabetes. Consequently, therapeutic strategies that preserve or restore erythrocyte integrity are gaining traction as potential complements to conventional glycemic control. Such approaches may ultimately contribute to more comprehensive management of diabetes and its systemic ramifications.

Correspondence to: Adrian Solberg, Department of Biomedical Sciences, Northshore University, Oslo, Norway, E-mail: adrian.solberg.research@nsu-norway.edu

Received: 20-May-2025, Manuscript No. JHTD-25-39233; **Editor assigned:** 22-May-2025, PreQC No. JHTD-25-39233 (PQ); **Reviewed:** 05-Jun-2025, QC No. JHTD-25-39233; **Revised:** 12-Jun-2025, Manuscript No. JHTD-25-39233 (R); **Published:** 19-Jun-2025, DOI: 10.35248/2329-8790.25.13.671

Citation: Solberg A (2025). Department of Biomedical Sciences, Northshore University, Oslo, Norway. J Hematol Thrombo Dis.13:671.